iGEN
Visit IGEN World Explore IGEN Expo
EXPLORE UPGRADE PLANS
BREAKING
India seeks to cut reliance on imported strawberry varieties with indigenous breeding Burnham Confirms Pragmatic North Sea Oil Stance in Trump Call, Fueling Drilling Debate Leaked Memo Links Iranian Hackers to Minnesota Water Utility Cyberattacks Everyone Is Freaking Out About OpenAI and Anthropic’s Race for Dominance Govt Debunks AI-Generated Fake Video of Finance Minister Nirmala Sitharaman Promoting Investment Scheme UPS Unveils Digital Tools to Attract Small Businesses Amid Strategic Shift from Low-Margin E-Commerce CPKC sets second-quarter revenue record as operating income rises 10% Your Freight Funnel Is Leaking Margin: What Your Reports Won't Show Transponders Off: Saudi Crude Tankers for India Exit Red Sea 'Dark' to Avoid Houthi Blockade Nvidia’s Open Source Alliance Snubs OpenAI and Anthropic, Deepening AI Rift India seeks to cut reliance on imported strawberry varieties with indigenous breeding Burnham Confirms Pragmatic North Sea Oil Stance in Trump Call, Fueling Drilling Debate Leaked Memo Links Iranian Hackers to Minnesota Water Utility Cyberattacks Everyone Is Freaking Out About OpenAI and Anthropic’s Race for Dominance Govt Debunks AI-Generated Fake Video of Finance Minister Nirmala Sitharaman Promoting Investment Scheme UPS Unveils Digital Tools to Attract Small Businesses Amid Strategic Shift from Low-Margin E-Commerce CPKC sets second-quarter revenue record as operating income rises 10% Your Freight Funnel Is Leaking Margin: What Your Reports Won't Show Transponders Off: Saudi Crude Tankers for India Exit Red Sea 'Dark' to Avoid Houthi Blockade Nvidia’s Open Source Alliance Snubs OpenAI and Anthropic, Deepening AI Rift
Home ›› Topics ›› glp-1

Topic

glp-1

3 stories
Ozempic-maker Novo Nordisk sues Eli Lilly for false advertising over weight-loss drug claims Manufacturing
Pharmaceuticals #novo nordisk#eli lilly

Ozempic-maker Novo Nordisk sues Eli Lilly for false advertising over weight-loss drug claims

Novo Nordisk has sued Eli Lilly, alleging false advertising in Eli Lilly's campaigns that compare weight-loss and diabetes drugs. Novo claims Eli Lilly intentionally used outdated studies and omitted higher-dose options to create a misleading impression of superiority. The lawsuit seeks to pull the ads and run corrective advertising.

Jul 21, 2026 1 source
Just About Anyone Can Sell GLP-1s Online Now: Turnkey Telehealth Sparks Market Flood Manufacturing
Pharmaceuticals #glp-1#ozempic

Just About Anyone Can Sell GLP-1s Online Now: Turnkey Telehealth Sparks Market Flood

The rise of turnkey telehealth services is enabling companies with no medical background—from search platforms like JustAnswer to dating apps like Grindr—to sell GLP-1 drugs online. Infrastructure firms handle software, clinician networks, and compliance, allowing new entrants to launch in as little as three hours. The trend is accelerating rapidly, with one provider reporting a minimum of one new brand launch per day.

Jul 1, 2026 1 source
GLP-1 Online Scams Entangle Unsuspecting Patients, Triggering Supply Chain and R E-Commerce & Marketplaces
Cross-Border E-Commerce #glp-1#weight loss drugs

GLP-1 Online Scams Entangle Unsuspecting Patients, Triggering Supply Chain and R

A WIRED investigation into online telehealth provider FitRx/Zealthy reveals a pattern of deceptive billing and shipment of unwanted GLP-1 drugs like tirzepatide. Customers face denied refunds due to 'supply chain and privacy' policies, despite FDA and FTC oversight. The case highlights risks in the booming online weight-loss drug market projected to reach $150 billion.

Jun 12, 2026 1 source